ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

autogene cevumeran

Also written as “Autogene cevumeran”, “Autogene Cevumeran” and “RO7198457 intravenous (IV)”.

Its studies are mostly in Melanoma · Colorectal Neoplasms · Adenocarcinoma, led by 2 companies.

Drug pageAutogene cevumeran: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jan 7, 20195 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche42 open or runningphase 2since Jan 7, 2019Sep 19, 2017Nov 10, 2027phase 2 · NCT06534983
BioNTechits history only11 open or runningphase 2since Jul 20, 2020Jul 20, 2020Nov 2026phase 2 · NCT04486378
  • Named in Hoffmann-La Roche’s own pipeline as RG6180 autogene cevumeran (BioNTech), phase 2, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2017First study: phase 1 study in MelanomaFirst studyNCT03289962 · 273 enrolled · United States, Belgium, Canada and more
  2. Jan 7, 2019Phase 2 study in Advanced MelanomaNCT03815058 · 131 enrolled · United States, Australia, Belgium and more
  3. Dec 9, 2019Named autogene cevumeranINNProposed as its International Nonproprietary Name in WHO's List 122
  4. Jul 21, 2023Phase 2 study in AdenocarcinomaNCT05968326 · 260 enrolled · United States, Belgium, Canada and more
  5. Jul 30, 2024Phase 2 study in Muscle-invasive Urothelial CarcinomaNCT06534983 · 62 enrolled · United States, Argentina, Australia and more

Ahead

  1. Nov 10, 2027Primary completion: phase 2 study in Muscle-invasive Urothelial CarcinomaNCT06534983
  2. Jan 1, 2031Primary completion: phase 2 study in AdenocarcinomaNCT05968326

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up…”NCIt, read by Claude

Studies

All 4 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06534983Muscle-invasive Urothelial Carcinoma · United States, Argentina, Australia and more2Active, not recruitingNov 10, 202762
NCT05968326Adenocarcinoma · United States, Belgium, Canada and more2Active, not recruitingJan 1, 2031260
NCT03815058Advanced Melanoma · United States, Australia, Belgium and more2CompletedJan 21, 2025131
NCT03289962Melanoma · United States, Belgium, Canada and more1CompletedJul 1, 2025273

How it is read

Names in the registry

  • “Autogene cevumeran”, 3 entries
  • “Autogene Cevumeran”, 1 entry
  • “RO7198457 intravenous (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.